<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757665</url>
  </required_header>
  <id_info>
    <org_study_id>2012-02</org_study_id>
    <nct_id>NCT01757665</nct_id>
  </id_info>
  <brief_title>ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)</brief_title>
  <acronym>COMMENCE</acronym>
  <official_title>ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform (COMMENCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to confirm that the modifications to tissue processing, valve
      sterilization and packaging do not raise any new questions of safety and effectiveness in
      subjects who require replacement of their native or prosthetic aortic or mitral valve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, prospective, single arm trial - Up to seven hundred (700) aortic valve
      replacement (AVR) subjects and up to one hundred seventy-five (175) mitral valve replacement
      (MVR) subjects at up to forty (40) clinical sites will be enrolled. The trial will include
      male and female patients, 18 years or older, requiring replacement for a diseased, damaged,
      or malfunctioning native or prosthetic aortic or mitral valve. Patients will be followed and
      assessed after implant for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Structural Valve Deterioration</measure>
    <time_frame>1 Year Post Implant</time_frame>
    <description>The rate of implanted subjects that experience structural valve deterioration (SVD) of the trial valve by the time of the post operative day (POD) 390 follow‚Äêup visit. Structural valve deterioration includes dysfunction or deterioration intrinsic to the valve. Examples of SVD includes complications such as wear, fracture, calcification, leaflet tear.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Early Adverse Events</measure>
    <time_frame>Events occuring within 30 days of procedure</time_frame>
    <description>Number of subjects with early adverse events occurring within 30 days of procedure divided by the number of enrolled subjects times 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Late Adverse Events Divided by Late Patient Years</measure>
    <time_frame>Events occurring &gt;= 31 days and up through 3 years post-implant</time_frame>
    <description>Number of late events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject's Average Mean Gradient Measurements - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Year Post Implant</time_frame>
    <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Mean Gradient Measurements - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Mean gradient is the average flow of blood through the mitral valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Peak Gradients Measurements Over Time - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Peak Gradients Measurements Over Time - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Peak gradient is the maximum value measured of flow of blood through the mitral valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Effective Orifice Area Measurements - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Effective Orifice Area Measurements - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the mitral valve. Effective orifice area is evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the mitral valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Performance Index Measurements - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Performance index is defined as the subject's effective orifice area (the cross sectional area of the blood flow downstream of the aortic valve) divided by the subject's native orifice area. Effective orifice area is evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Performance Index Measurements - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Performance index is defined as the subject's effective orifice area (the crosssectional area of the blood flow downstream of the mitral valve) divided by the subject's native orifice area. Effective orifice area is evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Cardiac Output Over Time - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Cardiac Output Over Time - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Cardiac Index Over Time- 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area (BSA), thus relating heart performance to the size of the individual.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Cardiac Index Over Time - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area(BSA), thus relating heart performance to the size of the individual.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Amount of Total Valvular Regurgitation Over Time - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Amount of Total Valvular Regurgitation Over Time - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Mitral valvular regurgitation occurs when the mitral valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Mitral valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Amount of Paravalvular Leak Over Time - 11000A</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Amount of Paravalvular Leak Over Time - 11000M</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline</measure>
    <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
    <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Score at Baseline and 1 Year on the Quality of Life Survey</measure>
    <time_frame>Baseline and one year post-implant</time_frame>
    <description>The Medical Outcomes Study Short-Form 12 (SF-12) contains two components - the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
The SF-12 Physical Component Summary questionnaire scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status.
The SF-12 Mental Component Summary scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average White Blood Cell Count</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
    <description>Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Red Blood Cells Count</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
    <description>Laboratory Analysis of Red Blood Cell (RBC) Count on blood drawn from subjects; RBC carry oxygen.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Hematocrit Percentage</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
    <description>Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. Hematocrit is the proportion of red blood cells to the plasma (liquid portion of the blood).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Hemoglobin Count</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
    <description>Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Platelet Count</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year, and 2 Years</time_frame>
    <description>Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Plasma Free Hemoglobin</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
    <description>Laboratory Analysis of Plasma Free Hemoglobin on blood drawn from subjects. This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average International Normalized Ratio</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
    <description>Laboratory Analysis of International Normalized Ratio (INR) on blood drawn from subjects. The INR is a calculation based on results of a prothrombin time (PT). The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot. INR results will vary according to a person's age, the medicines they take, and any health problems they may have. In general, the higher the INR number, the longer it takes for the blood to clot. In healthy people an INR of 1.1 or below is considered normal. An INR range of 2.0 to 3.0 is generally an effective therapeutic range for people taking blood thinner medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Partial Thromboplastin Time</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
    <description>Laboratory Analysis of partial thromboplastin time (PTT) on blood drawn from subjects. PTT is a blood test that looks at how long it takes for the blood to clot.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Prothrombin Time</measure>
    <time_frame>Baseline, Discharge, 3 Months, 1 Year, and 2 Years</time_frame>
    <description>Laboratory Analysis of Prothrombin Time (PT) on blood drawn from subjects. The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjects Average Serum Glycerol Levels</measure>
    <time_frame>Pre-Implant (post-heparinization) and Post-Implant (between 60 and 120 minutes after heart was restarted)</time_frame>
    <description>Laboratory analysis of serum glycerol in blood drawn from subjects. This blood test measures the amount of glycerol (a naturally occurring carbohydrate, that can be used as a fuel source by the body) in the serum (liquid portion of the blood).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">777</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Mitral Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aortic/Mitral valve replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M</intervention_name>
    <description>Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M</description>
    <arm_group_label>Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

        Inclusion Criteria:

          1. Is 18 years or older

          2. Provides written informed consent prior to trial procedures

          3. Agrees to attend all follow-up assessments for up to 5 years and is willing to comply
             with specified follow-up evaluations at clinical investigational sites that are
             participating in the COMMENCE trial and/or obtain the protocol-specified diagnostic
             tests at centers that are under the same IRB or the same healthcare system

          4. Diagnosed with aortic or mitral valve disease requiring valve replacement based on
             pre- operative evaluation

          5. Scheduled to undergo planned aortic or mitral valve replacement with or without
             concomitant bypass surgery

          6. Scheduled to undergo planned aortic valve replacement with or without resection and
             replacement of the ascending aorta from the sinotubular junction and without the need
             for circulatory arrest for hemi arch or arch replacement

        Exclusion criteria:

        A subject meeting any of the following criteria shall be excluded:

          1. Requires emergency surgery

          2. Requires planned multiple valve replacement/ repair (with the exception of mitral
             valve replacement with tricuspid valve repair)

          3. Has prior valve surgery, which included implant of a bioprosthetic valve, mechanical
             valve, or annuloplasty ring that will remain in situ

          4. Requires a surgical procedure outside of the cardiac area (e.g. vascular bypass)

          5. Requires surgical replacement of the aortic root

          6. Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months to the
             scheduled aortic or mitral valve replacement surgery

          7. Has renal insufficiency as determined by creatinine (S-Cr) level ‚â• 2.5 mg/dL or end
             -stage renal disease requiring chronic dialysis at screening visit

          8. Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient
             ischemic attack (TIA) within 6 months (180 days) prior to planned valve surgery

          9. Has acute myocardial infarction (MI) within 30 days prior to planned valve surgery

         10. Has presence of non-cardiac disease limiting life expectancy to less than 12 months

         11. Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM)

         12. Diagnosed with abnormal calcium metabolism and hyperparathyroidism

         13. Exhibits left ventricular ejection fraction ‚â§ 20% as validated by diagnostic procedure
             prior to planned valve surgery

         14. Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation

         15. Hemodynamic or respiratory instability requiring inotropic support, mechanical
             circulatory support, or mechanical ventilation within 30 days prior to planned valve
             surgery

         16. Documented leukopenia (WBC &lt; 3.5x 10¬≥/ŒºL), acute anemia (Hgb &lt; 10.0 gm/dL or 6 mmol/L)
             or thrombocytopenia (platelet count &lt; 50x 10¬≥/ŒºL) accompanied by history of bleeding
             diathesis and coagulopathy

         17. Has prior organ transplant or is currently an organ transplant candidate

         18. Current or recent participation (within 6 weeks prior to surgery) in another drug or
             device trial

         19. Was previously implanted with trial device (Model 11000A or Model 11000M)

         20. Pregnant (female subject of childbearing potential only), lactating or planning to
             become pregnant during the duration of participation in trial

         21. Currently incarcerated or unable to give voluntary informed consent

         22. Documented history of substance (drug or alcohol) abuse within the last 5 years prior
             to implant

         23. Requires concomitant left ventricular assist device (LVAD) placement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Puskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Institute for Medical Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Board of Trustees of the Leland Stanford Junior University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>36131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/ Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Cardiovascular Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Health</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital of Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Qu√©bec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardinal Stefan Wyszynski Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure</url>
    <description>New York Heart Association Classification</description>
  </link>
  <link>
    <url>https://www.optum.com/solutions/life-sciences/answer-research/patient-insights/sf-health-surveys/sf-12v2-health-survey.html?s=PPC&amp;pstc=optum:PP:LS_4.6_2019:g:LS:Frm:19iiggo01rr22&amp;ppcid=sf%2012&amp;adid=247796573650&amp;adgroupid=52618954298&amp;campaignid=1036340767&amp;o=optum:PP:LS_4.6_2019:frm:LS:Frm:19iiggo01rr22&amp;gclid=Cj0KCQiA-4nuBRCnARIsAHwyuPr-t3R-daJIiCgcyjnvZgLLdNHPgd719995kRxW8gwzNXLN5KYW99QaAhzqEALw_wcB</url>
    <description>Short Form Health Survey (SF-12)</description>
  </link>
  <results_reference>
    <citation>Puskas JD, Bavaria JE, Svensson LG, Blackstone EH, Griffith B, Gammie JS, Heimansohn DA, Sadowski J, Bartus K, Johnston DR, Rozanski J, Rosengart T, Girardi LN, Klodell CT, Mumtaz MA, Takayama H, Halkos M, Starnes V, Boateng P, Timek TA, Ryan W, Omer S, Smith CR; COMMENCE Trial Investigators. The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue. Eur J Cardiothorac Surg. 2017 Sep 1;52(3):432-439. doi: 10.1093/ejcts/ezx158.</citation>
    <PMID>28605428</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2012</study_first_posted>
  <results_first_submitted>December 11, 2019</results_first_submitted>
  <results_first_submitted_qc>December 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 27, 2019</results_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Mitral valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT01757665/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
          <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
        </group>
        <group group_id="P2">
          <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
          <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="694"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implanted With Device</title>
              <participants_list>
                <participants group_id="P1" count="689"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="694"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Still on Study - Visit Completed</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still on Study - Visit Pending</title>
              <participants_list>
                <participants group_id="P1" count="398"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still on Study - Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Explant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Implanted with Device</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This outcome is reported for enrolled subjects where data is available. Subjects were considered enrolled after meeting all the enrollment criteria, signing the informed consent, and after the surgeon assesses the subject‚Äôs anatomy, sizes the annulus, and determines that the trial valve can be implanted.</population>
      <group_list>
        <group group_id="B1">
          <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
          <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
        </group>
        <group group_id="B2">
          <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
          <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="694"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="777"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="11.6"/>
                    <measurement group_id="B2" value="68.9" spread="9.3"/>
                    <measurement group_id="B3" value="67.2" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="498"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="622"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="695"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Structural Valve Deterioration</title>
        <description>The rate of implanted subjects that experience structural valve deterioration (SVD) of the trial valve by the time of the post operative day (POD) 390 follow‚Äêup visit. Structural valve deterioration includes dysfunction or deterioration intrinsic to the valve. Examples of SVD includes complications such as wear, fracture, calcification, leaflet tear.</description>
        <time_frame>1 Year Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available. The SVD result combines the aortic and mitral implanted subjects. The study was powered for the combined cohort for this endpoint as there would be too few mitral subjects to report the arms separately.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Bioprosthesis, Models 11000A &amp; 11000M</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.
The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Structural Valve Deterioration</title>
          <description>The rate of implanted subjects that experience structural valve deterioration (SVD) of the trial valve by the time of the post operative day (POD) 390 follow‚Äêup visit. Structural valve deterioration includes dysfunction or deterioration intrinsic to the valve. Examples of SVD includes complications such as wear, fracture, calcification, leaflet tear.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available. The SVD result combines the aortic and mitral implanted subjects. The study was powered for the combined cohort for this endpoint as there would be too few mitral subjects to report the arms separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="716"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the rate of structural valve deterioration at one year is greater than 1%. The alternative hypothesis is that this rate is less than 1%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>percent of patients</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Upper 95% CI was calculated by the method of Clopper and Pearson, using the Beta distribution with parameters x + 1 and n - x where x is the number of SVD events by POD 390 and n is the number of subjects followed at the 1 year assessment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Early Adverse Events</title>
        <description>Number of subjects with early adverse events occurring within 30 days of procedure divided by the number of enrolled subjects times 100</description>
        <time_frame>Events occuring within 30 days of procedure</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Early Adverse Events</title>
          <description>Number of subjects with early adverse events occurring within 30 days of procedure divided by the number of enrolled subjects times 100</description>
          <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Valve Related Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Paravalvular Leak (OPC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Paravalvular Leak (OPC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-structural Valve Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reoperation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Explant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Late Adverse Events Divided by Late Patient Years</title>
        <description>Number of late events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).</description>
        <time_frame>Events occurring &gt;= 31 days and up through 3 years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Late Adverse Events Divided by Late Patient Years</title>
          <description>Number of late events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).</description>
          <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
          <units>percentage of events/late patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Valve Related Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Paravalvular Leak (OPC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Paravalvular Leak (OPC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-structural Valve Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reoperation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Explant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Mean Gradient Measurements - 11000A</title>
        <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
        <time_frame>3 Months, 1 Year, and 2 Year Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Mean Gradient Measurements - 11000A</title>
          <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="185"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="623"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="6.1"/>
                    <measurement group_id="O2" value="10.7" spread="4.2"/>
                    <measurement group_id="O3" value="9.4" spread="3.8"/>
                    <measurement group_id="O4" value="8.7" spread="3.4"/>
                    <measurement group_id="O5" value="6.8" spread="2.6"/>
                    <measurement group_id="O6" value="4.7" spread="1.3"/>
                    <measurement group_id="O7" value="9.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="69"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="7.8"/>
                    <measurement group_id="O2" value="12.6" spread="4.7"/>
                    <measurement group_id="O3" value="10.1" spread="3.8"/>
                    <measurement group_id="O4" value="9.6" spread="5.2"/>
                    <measurement group_id="O5" value="8.2" spread="3.5"/>
                    <measurement group_id="O7" value="10.4" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="6.4"/>
                    <measurement group_id="O2" value="11.2" spread="4.0"/>
                    <measurement group_id="O3" value="9.9" spread="4.4"/>
                    <measurement group_id="O4" value="9.2" spread="3.4"/>
                    <measurement group_id="O5" value="8.3" spread="3.5"/>
                    <measurement group_id="O7" value="10.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Mean Gradient Measurements - 11000M</title>
        <description>Mean gradient is the average flow of blood through the mitral valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Mean Gradient Measurements - 11000M</title>
          <description>Mean gradient is the average flow of blood through the mitral valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.7"/>
                    <measurement group_id="O2" value="4.1" spread="1.7"/>
                    <measurement group_id="O3" value="4.0" spread="1.5"/>
                    <measurement group_id="O4" value="3.4" spread="1.3"/>
                    <measurement group_id="O5" value="3.3" spread="1.4"/>
                    <measurement group_id="O6" value="4.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.2"/>
                    <measurement group_id="O2" value="4.1" spread="1.4"/>
                    <measurement group_id="O3" value="4.1" spread="1.5"/>
                    <measurement group_id="O4" value="3.9" spread="2.0"/>
                    <measurement group_id="O5" value="3.3" spread="1.4"/>
                    <measurement group_id="O6" value="4.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.9" spread="1.8"/>
                    <measurement group_id="O3" value="3.8" spread="1.0"/>
                    <measurement group_id="O4" value="3.5" spread="0.8"/>
                    <measurement group_id="O5" value="3.4" spread="2.5"/>
                    <measurement group_id="O6" value="3.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Peak Gradients Measurements Over Time - 11000A</title>
        <description>Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Peak Gradients Measurements Over Time - 11000A</title>
          <description>Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="185"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="623"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="12.3"/>
                    <measurement group_id="O2" value="21.7" spread="8.2"/>
                    <measurement group_id="O3" value="18.8" spread="6.9"/>
                    <measurement group_id="O4" value="17.5" spread="6.3"/>
                    <measurement group_id="O5" value="13.8" spread="4.9"/>
                    <measurement group_id="O6" value="10.1" spread="3.0"/>
                    <measurement group_id="O7" value="18.4" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="132"/>
                    <count group_id="O5" value="69"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="16.3"/>
                    <measurement group_id="O2" value="25.2" spread="8.9"/>
                    <measurement group_id="O3" value="20.1" spread="7.5"/>
                    <measurement group_id="O4" value="19.2" spread="8.9"/>
                    <measurement group_id="O5" value="16.7" spread="6.9"/>
                    <measurement group_id="O7" value="20.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="12.0"/>
                    <measurement group_id="O2" value="22.0" spread="7.5"/>
                    <measurement group_id="O3" value="19.8" spread="8.5"/>
                    <measurement group_id="O4" value="18.2" spread="6.0"/>
                    <measurement group_id="O5" value="16.4" spread="6.6"/>
                    <measurement group_id="O7" value="20.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Peak Gradients Measurements Over Time - 11000M</title>
        <description>Peak gradient is the maximum value measured of flow of blood through the mitral valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Peak Gradients Measurements Over Time - 11000M</title>
          <description>Peak gradient is the maximum value measured of flow of blood through the mitral valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="1.4"/>
                    <measurement group_id="O2" value="9.8" spread="4.0"/>
                    <measurement group_id="O3" value="10.2" spread="4.2"/>
                    <measurement group_id="O4" value="9.0" spread="2.8"/>
                    <measurement group_id="O5" value="17.4" spread="22.1"/>
                    <measurement group_id="O6" value="10.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="3.0"/>
                    <measurement group_id="O2" value="9.9" spread="3.2"/>
                    <measurement group_id="O3" value="10.4" spread="3.7"/>
                    <measurement group_id="O4" value="10.2" spread="5.5"/>
                    <measurement group_id="O5" value="9.0" spread="4.1"/>
                    <measurement group_id="O6" value="10.1" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9.5" spread="4.7"/>
                    <measurement group_id="O3" value="10.5" spread="3.4"/>
                    <measurement group_id="O4" value="6.6" spread="1.2"/>
                    <measurement group_id="O5" value="8.3" spread="3.4"/>
                    <measurement group_id="O6" value="9.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Effective Orifice Area Measurements - 11000A</title>
        <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Effective Orifice Area Measurements - 11000A</title>
          <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>Centimeters Squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="184"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="620"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.4"/>
                    <measurement group_id="O2" value="1.5" spread="0.4"/>
                    <measurement group_id="O3" value="1.7" spread="0.4"/>
                    <measurement group_id="O4" value="1.8" spread="0.5"/>
                    <measurement group_id="O5" value="2.3" spread="0.7"/>
                    <measurement group_id="O6" value="2.5" spread="0.8"/>
                    <measurement group_id="O7" value="1.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.3" spread="0.3"/>
                    <measurement group_id="O3" value="1.6" spread="0.4"/>
                    <measurement group_id="O4" value="1.8" spread="0.5"/>
                    <measurement group_id="O5" value="2.2" spread="0.6"/>
                    <measurement group_id="O7" value="1.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.4"/>
                    <measurement group_id="O2" value="1.3" spread="0.3"/>
                    <measurement group_id="O3" value="1.6" spread="0.4"/>
                    <measurement group_id="O4" value="1.9" spread="0.5"/>
                    <measurement group_id="O5" value="1.8" spread="0.5"/>
                    <measurement group_id="O7" value="1.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Effective Orifice Area Measurements - 11000M</title>
        <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the mitral valve. Effective orifice area is evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Effective Orifice Area Measurements - 11000M</title>
          <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the mitral valve. Effective orifice area is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>Centimeters Squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.3"/>
                    <measurement group_id="O2" value="1.4" spread="0.4"/>
                    <measurement group_id="O3" value="1.6" spread="0.6"/>
                    <measurement group_id="O4" value="1.6" spread="0.4"/>
                    <measurement group_id="O5" value="1.8" spread="0.4"/>
                    <measurement group_id="O6" value="1.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.4"/>
                    <measurement group_id="O2" value="1.2" spread="0.3"/>
                    <measurement group_id="O3" value="1.5" spread="0.6"/>
                    <measurement group_id="O4" value="1.4" spread="0.5"/>
                    <measurement group_id="O5" value="1.5" spread="0.7"/>
                    <measurement group_id="O6" value="1.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.3" spread="0.5"/>
                    <measurement group_id="O3" value="1.4" spread="0.4"/>
                    <measurement group_id="O4" value="1.6" spread="0.0"/>
                    <measurement group_id="O5" value="1.2" spread="0.3"/>
                    <measurement group_id="O6" value="1.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000A</title>
        <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000A</title>
          <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="184"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="620"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.3"/>
                    <measurement group_id="O2" value="0.8" spread="0.3"/>
                    <measurement group_id="O3" value="0.9" spread="0.3"/>
                    <measurement group_id="O4" value="0.9" spread="0.3"/>
                    <measurement group_id="O5" value="1.1" spread="0.3"/>
                    <measurement group_id="O6" value="1.1" spread="0.3"/>
                    <measurement group_id="O7" value="0.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.1"/>
                    <measurement group_id="O2" value="0.7" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.2"/>
                    <measurement group_id="O4" value="0.8" spread="0.2"/>
                    <measurement group_id="O5" value="1.0" spread="0.3"/>
                    <measurement group_id="O7" value="0.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.3"/>
                    <measurement group_id="O2" value="0.7" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.2"/>
                    <measurement group_id="O4" value="0.9" spread="0.2"/>
                    <measurement group_id="O5" value="0.8" spread="0.2"/>
                    <measurement group_id="O7" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000M</title>
        <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the mitral valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Effective Orifice Area Index (EOAI) Measurements - 11000M</title>
          <description>Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the mitral valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.3"/>
                    <measurement group_id="O3" value="0.8" spread="0.3"/>
                    <measurement group_id="O4" value="0.8" spread="0.2"/>
                    <measurement group_id="O5" value="0.9" spread="0.2"/>
                    <measurement group_id="O6" value="0.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.7" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.3"/>
                    <measurement group_id="O4" value="0.7" spread="0.2"/>
                    <measurement group_id="O5" value="0.7" spread="0.3"/>
                    <measurement group_id="O6" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.8" spread="0.3"/>
                    <measurement group_id="O3" value="0.7" spread="0.2"/>
                    <measurement group_id="O4" value="0.9" spread="0.2"/>
                    <measurement group_id="O5" value="0.6" spread="0.1"/>
                    <measurement group_id="O6" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Performance Index Measurements - 11000A</title>
        <description>Performance index is defined as the subject's effective orifice area (the cross sectional area of the blood flow downstream of the aortic valve) divided by the subject's native orifice area. Effective orifice area is evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Performance Index Measurements - 11000A</title>
          <description>Performance index is defined as the subject's effective orifice area (the cross sectional area of the blood flow downstream of the aortic valve) divided by the subject's native orifice area. Effective orifice area is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="184"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="620"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.9" spread="0.2"/>
                    <measurement group_id="O3" value="0.9" spread="0.2"/>
                    <measurement group_id="O4" value="0.9" spread="0.2"/>
                    <measurement group_id="O5" value="0.9" spread="0.3"/>
                    <measurement group_id="O6" value="0.8" spread="0.3"/>
                    <measurement group_id="O7" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="155"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.2"/>
                    <measurement group_id="O4" value="0.8" spread="0.2"/>
                    <measurement group_id="O5" value="0.9" spread="0.2"/>
                    <measurement group_id="O7" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.3"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.2"/>
                    <measurement group_id="O4" value="0.9" spread="0.2"/>
                    <measurement group_id="O5" value="0.7" spread="0.2"/>
                    <measurement group_id="O7" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Performance Index Measurements - 11000M</title>
        <description>Performance index is defined as the subject's effective orifice area (the crosssectional area of the blood flow downstream of the mitral valve) divided by the subject's native orifice area. Effective orifice area is evaluated by echocardiography over time.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Performance Index Measurements - 11000M</title>
          <description>Performance index is defined as the subject's effective orifice area (the crosssectional area of the blood flow downstream of the mitral valve) divided by the subject's native orifice area. Effective orifice area is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>cm^2/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.6" spread="0.2"/>
                    <measurement group_id="O3" value="0.6" spread="0.2"/>
                    <measurement group_id="O4" value="0.5" spread="0.1"/>
                    <measurement group_id="O5" value="0.6" spread="0.1"/>
                    <measurement group_id="O6" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="0.6" spread="0.2"/>
                    <measurement group_id="O3" value="0.6" spread="0.2"/>
                    <measurement group_id="O4" value="0.5" spread="0.2"/>
                    <measurement group_id="O5" value="0.5" spread="0.2"/>
                    <measurement group_id="O6" value="0.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.6" spread="0.2"/>
                    <measurement group_id="O3" value="0.6" spread="0.2"/>
                    <measurement group_id="O4" value="0.6" spread="0.0"/>
                    <measurement group_id="O5" value="0.4" spread="0.1"/>
                    <measurement group_id="O6" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Cardiac Output Over Time - 11000A</title>
        <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Cardiac Output Over Time - 11000A</title>
          <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="184"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="1.3"/>
                    <measurement group_id="O2" value="4.5" spread="1.2"/>
                    <measurement group_id="O3" value="4.7" spread="1.4"/>
                    <measurement group_id="O4" value="4.8" spread="1.2"/>
                    <measurement group_id="O5" value="5.2" spread="1.8"/>
                    <measurement group_id="O6" value="4.4" spread="1.2"/>
                    <measurement group_id="O7" value="4.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="156"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.9"/>
                    <measurement group_id="O2" value="4.7" spread="1.8"/>
                    <measurement group_id="O3" value="4.4" spread="1.2"/>
                    <measurement group_id="O4" value="4.8" spread="1.7"/>
                    <measurement group_id="O5" value="5.4" spread="1.6"/>
                    <measurement group_id="O7" value="4.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.1"/>
                    <measurement group_id="O2" value="4.3" spread="1.1"/>
                    <measurement group_id="O3" value="4.4" spread="1.2"/>
                    <measurement group_id="O4" value="4.9" spread="1.7"/>
                    <measurement group_id="O5" value="4.4" spread="1.4"/>
                    <measurement group_id="O7" value="4.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Cardiac Output Over Time - 11000M</title>
        <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Cardiac Output Over Time - 11000M</title>
          <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>Liters/Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.2"/>
                    <measurement group_id="O2" value="3.6" spread="0.9"/>
                    <measurement group_id="O3" value="4.3" spread="1.4"/>
                    <measurement group_id="O4" value="3.9" spread="0.8"/>
                    <measurement group_id="O5" value="4.6" spread="1.0"/>
                    <measurement group_id="O6" value="4.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.0"/>
                    <measurement group_id="O2" value="3.3" spread="1.1"/>
                    <measurement group_id="O3" value="4.4" spread="1.9"/>
                    <measurement group_id="O4" value="3.8" spread="1.1"/>
                    <measurement group_id="O5" value="3.8" spread="0.8"/>
                    <measurement group_id="O6" value="3.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.3" spread="1.1"/>
                    <measurement group_id="O3" value="4.1" spread="1.3"/>
                    <measurement group_id="O4" value="3.6" spread="0.3"/>
                    <measurement group_id="O5" value="3.3" spread="0.6"/>
                    <measurement group_id="O6" value="3.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Cardiac Index Over Time- 11000A</title>
        <description>Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area (BSA), thus relating heart performance to the size of the individual.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Cardiac Index Over Time- 11000A</title>
          <description>Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area (BSA), thus relating heart performance to the size of the individual.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>L/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="184"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.8"/>
                    <measurement group_id="O2" value="2.4" spread="0.7"/>
                    <measurement group_id="O3" value="2.4" spread="0.8"/>
                    <measurement group_id="O4" value="2.3" spread="0.6"/>
                    <measurement group_id="O5" value="2.4" spread="0.9"/>
                    <measurement group_id="O6" value="2.0" spread="0.4"/>
                    <measurement group_id="O7" value="2.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="156"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="67"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.5"/>
                    <measurement group_id="O2" value="2.5" spread="1.0"/>
                    <measurement group_id="O3" value="2.2" spread="0.6"/>
                    <measurement group_id="O4" value="2.2" spread="0.8"/>
                    <measurement group_id="O5" value="2.4" spread="0.7"/>
                    <measurement group_id="O7" value="2.3" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.8"/>
                    <measurement group_id="O2" value="2.3" spread="0.6"/>
                    <measurement group_id="O3" value="2.2" spread="0.7"/>
                    <measurement group_id="O4" value="2.3" spread="0.7"/>
                    <measurement group_id="O5" value="2.0" spread="0.6"/>
                    <measurement group_id="O7" value="2.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Cardiac Index Over Time - 11000M</title>
        <description>Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area(BSA), thus relating heart performance to the size of the individual.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Cardiac Index Over Time - 11000M</title>
          <description>Cardiac index is an assessment that divides the cardiac output from left ventricle in one minute by the person's body surface area(BSA), thus relating heart performance to the size of the individual.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>L/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.7"/>
                    <measurement group_id="O2" value="2.1" spread="0.6"/>
                    <measurement group_id="O3" value="2.2" spread="0.6"/>
                    <measurement group_id="O4" value="1.9" spread="0.4"/>
                    <measurement group_id="O5" value="2.1" spread="0.8"/>
                    <measurement group_id="O6" value="2.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.5"/>
                    <measurement group_id="O2" value="1.9" spread="0.5"/>
                    <measurement group_id="O3" value="2.2" spread="0.9"/>
                    <measurement group_id="O4" value="1.9" spread="0.5"/>
                    <measurement group_id="O5" value="1.8" spread="0.4"/>
                    <measurement group_id="O6" value="2.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.9" spread="0.7"/>
                    <measurement group_id="O3" value="2.1" spread="0.5"/>
                    <measurement group_id="O4" value="1.9" spread="0.3"/>
                    <measurement group_id="O5" value="1.6" spread="0.3"/>
                    <measurement group_id="O6" value="1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Amount of Total Valvular Regurgitation Over Time - 11000A</title>
        <description>Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Amount of Total Valvular Regurgitation Over Time - 11000A</title>
          <description>Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="186"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="623"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O4" value="162"/>
                    <measurement group_id="O5" value="69"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="531"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="131"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="112"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O7" value="385"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O7" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O7" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O7" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O7" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O7" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Amount of Total Valvular Regurgitation Over Time - 11000M</title>
        <description>Mitral valvular regurgitation occurs when the mitral valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Mitral valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Amount of Total Valvular Regurgitation Over Time - 11000M</title>
          <description>Mitral valvular regurgitation occurs when the mitral valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Mitral valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Amount of Paravalvular Leak Over Time - 11000A</title>
        <description>Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 19mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 21mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 23mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 25mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 27mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - 29mm</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O7">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A - Total</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Amount of Paravalvular Leak Over Time - 11000A</title>
          <description>Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="195"/>
                    <count group_id="O4" value="185"/>
                    <count group_id="O5" value="90"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="191"/>
                    <measurement group_id="O4" value="182"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="610"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="130"/>
                    <count group_id="O5" value="69"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="152"/>
                    <measurement group_id="O4" value="127"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O7" value="450"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O7" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Amount of Paravalvular Leak Over Time - 11000M</title>
        <description>Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 25mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 27mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O3">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 29mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O4">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 31mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O5">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - 33mm</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
          <group group_id="O6">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M - Total</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Amount of Paravalvular Leak Over Time - 11000M</title>
          <description>Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing.
Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.</description>
          <population>The outcome is reported for subjects who received the Model 11000M device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None</title>
                  <measurement_list>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+1 Trivial/Trace</title>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline</title>
        <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
        <time_frame>3 Months, 1 Year, and 2 Years Post Implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline</title>
          <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="645"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="431"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="509"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="331"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Score at Baseline and 1 Year on the Quality of Life Survey</title>
        <description>The Medical Outcomes Study Short-Form 12 (SF-12) contains two components - the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
The SF-12 Physical Component Summary questionnaire scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status.
The SF-12 Mental Component Summary scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status.</description>
        <time_frame>Baseline and one year post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Score at Baseline and 1 Year on the Quality of Life Survey</title>
          <description>The Medical Outcomes Study Short-Form 12 (SF-12) contains two components - the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
The SF-12 Physical Component Summary questionnaire scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status.
The SF-12 Mental Component Summary scale ranges from a maximum of 100, which reflects the best health status to a minimum of 0, which reflects the worst health status.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Health-Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="485"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="9.7"/>
                    <measurement group_id="O2" value="40.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health-1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="485"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="9.2"/>
                    <measurement group_id="O2" value="48.8" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health-Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="485"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="9.5"/>
                    <measurement group_id="O2" value="49.2" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health-1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="485"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" spread="8.5"/>
                    <measurement group_id="O2" value="52.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average White Blood Cell Count</title>
        <description>Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection.</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average White Blood Cell Count</title>
          <description>Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
          <units>10^3 cells /microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="689"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.9"/>
                    <measurement group_id="O2" value="7.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="682"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.8"/>
                    <measurement group_id="O2" value="10.4" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="621"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="1.7"/>
                    <measurement group_id="O2" value="7.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="1.9"/>
                    <measurement group_id="O2" value="7.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="1.8"/>
                    <measurement group_id="O2" value="7.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Red Blood Cells Count</title>
        <description>Laboratory Analysis of Red Blood Cell (RBC) Count on blood drawn from subjects; RBC carry oxygen.</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Red Blood Cells Count</title>
          <description>Laboratory Analysis of Red Blood Cell (RBC) Count on blood drawn from subjects; RBC carry oxygen.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or Model 11000M device where data is available.</population>
          <units>10^6 cells/microliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="689"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.5"/>
                    <measurement group_id="O2" value="4.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="682"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.5"/>
                    <measurement group_id="O2" value="3.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="621"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.5"/>
                    <measurement group_id="O2" value="4.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="498"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.5"/>
                    <measurement group_id="O2" value="4.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.5"/>
                    <measurement group_id="O2" value="4.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Hematocrit Percentage</title>
        <description>Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. Hematocrit is the proportion of red blood cells to the plasma (liquid portion of the blood).</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Hematocrit Percentage</title>
          <description>Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. Hematocrit is the proportion of red blood cells to the plasma (liquid portion of the blood).</description>
          <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="689"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="4.0"/>
                    <measurement group_id="O2" value="40.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="682"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="4.1"/>
                    <measurement group_id="O2" value="30.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="621"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="4.2"/>
                    <measurement group_id="O2" value="39.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" spread="4.1"/>
                    <measurement group_id="O2" value="41.3" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="3.9"/>
                    <measurement group_id="O2" value="42.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Hemoglobin Count</title>
        <description>Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells.</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Hemoglobin Count</title>
          <description>Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="689"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="1.5"/>
                    <measurement group_id="O2" value="13.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="682"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="1.4"/>
                    <measurement group_id="O2" value="9.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="621"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="1.6"/>
                    <measurement group_id="O2" value="12.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="1.7"/>
                    <measurement group_id="O2" value="13.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="1.5"/>
                    <measurement group_id="O2" value="14.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Platelet Count</title>
        <description>Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year, and 2 Years</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Platelet Count</title>
          <description>Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
          <units>10^3 platelets per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="689"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.6" spread="59.0"/>
                    <measurement group_id="O2" value="203.6" spread="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="682"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.7" spread="90.1"/>
                    <measurement group_id="O2" value="196.0" spread="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="621"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.3" spread="62.6"/>
                    <measurement group_id="O2" value="221.0" spread="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.7" spread="65.8"/>
                    <measurement group_id="O2" value="207.8" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.6" spread="54.5"/>
                    <measurement group_id="O2" value="204.0" spread="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Plasma Free Hemoglobin</title>
        <description>Laboratory Analysis of Plasma Free Hemoglobin on blood drawn from subjects. This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood).</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Plasma Free Hemoglobin</title>
          <description>Laboratory Analysis of Plasma Free Hemoglobin on blood drawn from subjects. This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood).</description>
          <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="629"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="18.4"/>
                    <measurement group_id="O2" value="19.8" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="560"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="12.2"/>
                    <measurement group_id="O2" value="7.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="22.2"/>
                    <measurement group_id="O2" value="10.6" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="463"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="25.5"/>
                    <measurement group_id="O2" value="8.6" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="33.9"/>
                    <measurement group_id="O2" value="20.5" spread="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average International Normalized Ratio</title>
        <description>Laboratory Analysis of International Normalized Ratio (INR) on blood drawn from subjects. The INR is a calculation based on results of a prothrombin time (PT). The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot. INR results will vary according to a person's age, the medicines they take, and any health problems they may have. In general, the higher the INR number, the longer it takes for the blood to clot. In healthy people an INR of 1.1 or below is considered normal. An INR range of 2.0 to 3.0 is generally an effective therapeutic range for people taking blood thinner medication.</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average International Normalized Ratio</title>
          <description>Laboratory Analysis of International Normalized Ratio (INR) on blood drawn from subjects. The INR is a calculation based on results of a prothrombin time (PT). The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot. INR results will vary according to a person's age, the medicines they take, and any health problems they may have. In general, the higher the INR number, the longer it takes for the blood to clot. In healthy people an INR of 1.1 or below is considered normal. An INR range of 2.0 to 3.0 is generally an effective therapeutic range for people taking blood thinner medication.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="672"/>
                    <count group_id="O2" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="579"/>
                    <count group_id="O2" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.4"/>
                    <measurement group_id="O2" value="1.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="479"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.5"/>
                    <measurement group_id="O2" value="1.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.6"/>
                    <measurement group_id="O2" value="1.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Partial Thromboplastin Time</title>
        <description>Laboratory Analysis of partial thromboplastin time (PTT) on blood drawn from subjects. PTT is a blood test that looks at how long it takes for the blood to clot.</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year and 2 Year</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Partial Thromboplastin Time</title>
          <description>Laboratory Analysis of partial thromboplastin time (PTT) on blood drawn from subjects. PTT is a blood test that looks at how long it takes for the blood to clot.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="608"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="6.0"/>
                    <measurement group_id="O2" value="35.1" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="489"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="8.5"/>
                    <measurement group_id="O2" value="37.2" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="399"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="15.8"/>
                    <measurement group_id="O2" value="36.0" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="5.7"/>
                    <measurement group_id="O2" value="35.3" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="14.4"/>
                    <measurement group_id="O2" value="33.7" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Prothrombin Time</title>
        <description>Laboratory Analysis of Prothrombin Time (PT) on blood drawn from subjects. The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot.</description>
        <time_frame>Baseline, Discharge, 3 Months, 1 Year, and 2 Years</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
            <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Prothrombin Time</title>
          <description>Laboratory Analysis of Prothrombin Time (PT) on blood drawn from subjects. The PT is a blood test that measures the time it takes for the plasma (liquid portion of the blood) to clot.</description>
          <population>The outcome is reported for subjects who received the Model 11000A or 11000M device where data is available.</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="664"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="2.5"/>
                    <measurement group_id="O2" value="16.2" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="577"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="5.0"/>
                    <measurement group_id="O2" value="20.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="475"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="7.4"/>
                    <measurement group_id="O2" value="21.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="5.7"/>
                    <measurement group_id="O2" value="19.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="6.4"/>
                    <measurement group_id="O2" value="17.3" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjects Average Serum Glycerol Levels</title>
        <description>Laboratory analysis of serum glycerol in blood drawn from subjects. This blood test measures the amount of glycerol (a naturally occurring carbohydrate, that can be used as a fuel source by the body) in the serum (liquid portion of the blood).</description>
        <time_frame>Pre-Implant (post-heparinization) and Post-Implant (between 60 and 120 minutes after heart was restarted)</time_frame>
        <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Edwards Pericardial Bioprosthesis, Model 11000A</title>
            <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Average Serum Glycerol Levels</title>
          <description>Laboratory analysis of serum glycerol in blood drawn from subjects. This blood test measures the amount of glycerol (a naturally occurring carbohydrate, that can be used as a fuel source by the body) in the serum (liquid portion of the blood).</description>
          <population>The outcome is reported for subjects who received the Model 11000A device where data is available.</population>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Implant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.4" spread="270.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Implant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.6" spread="345.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events occurring from baseline through three years post implant for the 11000A, and four years post implant for 11000M.</time_frame>
      <desc>Adverse event table is reported for Subjects who received the Model 11000A or 11000M Device.</desc>
      <group_list>
        <group group_id="E1">
          <title>Edwards Pericardial Aortic Bioprosthesis, Model 11000A</title>
          <description>The Edwards Pericardial Aortic Bioprosthesis, Model 11000A, is indicated for patients who require replacement of their native or prosthetic aortic valve.</description>
        </group>
        <group group_id="E2">
          <title>Edwards Pericardial Mitral Bioprosthesis, Model 11000M</title>
          <description>The Edwards Pericardial Mitral Bioprosthesis, Model 11000M, is indicated for patients who require replacement of their native or prosthetic mitral valve.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="689"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="317" subjects_at_risk="689"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia - Bleeding related - Major</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Anemia - Bleeding related - Minor</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Anemia - Non-bleeding related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Cardiovascular - Major</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Cardiovascular - Minor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Gastrointestinal lower - Major</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Gastrointestinal lower - Minor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Gastrointestinal upper - Major</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Genitourinary - Minor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Musculoskeletal/Dermatological - Major (e.g. ecchymosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Neurological - Minor (e.g. CVA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Peripheral vascular - Minor (e.g. nosebleeds; hematomas)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Pulmonary/Respiratory - Major (e.g. hemothorax)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Blood sepsis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="689"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Blood/Lymphatic - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia - Heparin Induced (HIT)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia - Non-heparin induced</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina, stable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Angina, unstable</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Atrial flutter</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - AV block - 1st degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - AV block - 2nd degree</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - AV block - 3rd degree</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="689"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bundle branch block - Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bundle branch block - Right</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="689"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Paroxysmal Atrial Fibrillation (PAF)</sub_title>
                <counts group_id="E1" events="41" subjects_affected="39" subjects_at_risk="689"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Permanent atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Persistent atrial fibrillation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="689"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Supraventricular Tachycardia (SVT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Tachy-bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Tachycardia - Ventricular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiac decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiovascular - Other</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="689"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Coronary artery ostial obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Heart failure - Acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Heart Failure - Chronic (CHF)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="689"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypertension - Systemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="689"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pericardial effusion - Major</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pericardial effusion - Minor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pericardial tamponade</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Bilateral</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Left</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Right</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Tricuspid-indeterminate +4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thromboembolic event - Other - Central - No paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thromboembolic event - Other - Peripheral - No paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thromboembolic event - Stroke</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thromboembolic event - Transient Ischemic Attack (TIA)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Valve thrombosis - Aortic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary (gallbladder)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Endocrine complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Esophageal rupture/tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hepatic complication - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Metabolic complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pancreatic complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Splenic complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer - Newly diagnosed</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cancer - Progression of underlying disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Fever - Unknown origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Nonspecific, unknown, or other body system - Other complication</sub_title>
                <counts group_id="E1" events="51" subjects_affected="43" subjects_at_risk="689"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>NSD - Paravalvular leak +2 Minor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>NSD - Paravalvular leak +3 Major</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>NSD - Paravalvular leak +4 Major</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>SVD - Study valve leaflet tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vision disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture/Break</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Infection/Inflammation - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Muscular skeletal/Dermatologic - Other</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="689"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Sternal wound/Thoracic infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Wound infection - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Psychiatric disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary - Other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal failure - Acute</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="689"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal failure - Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism - Bilateral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary/Respiratory - Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory dysfunction/Insufficiency</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Acute Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - COPD</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Hemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="689"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Pneumothorax</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory infection - Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory infection - Upper (URI)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular - Deep Vein Thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="689"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="689"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="542" subjects_at_risk="589"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia - Bleeding related - Major</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Anemia - Bleeding related - Minor</sub_title>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="589"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Anemia - Non-bleeding related</sub_title>
                <counts group_id="E1" events="61" subjects_affected="61" subjects_at_risk="589"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Cardiovascular - Major</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Cardiovascular - Minor</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Gastrointestinal lower - Minor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Gastrointestinal upper - Minor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Genitourinary - Major</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Genitourinary - Minor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Musculoskeletal/Dermatological - Minor (e.g. ecchymosis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Neurological - Major (e.g. CVA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Peripheral vascular - Minor (e.g. nosebleeds; hematomas)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bleeding - Pulmonary/Respiratory - Minor (e.g. hemothorax)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Blood sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Blood/Lymphatic - Other</sub_title>
                <counts group_id="E1" events="159" subjects_affected="138" subjects_at_risk="589"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia - Heparin Induced (HIT)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia - Non-heparin induced</sub_title>
                <counts group_id="E1" events="134" subjects_affected="134" subjects_at_risk="589"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina, stable</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Angina, unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Atrial flutter</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="589"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - AV block - 1st degree</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="589"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - AV block - 2nd degree</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="589"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - AV block - 3rd degree</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bradycardia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="589"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bundle branch block - Left</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Bundle branch block - Right</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Other</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="589"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Pacemaker/ICD malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Paroxysmal Atrial Fibrillation (PAF)</sub_title>
                <counts group_id="E1" events="137" subjects_affected="136" subjects_at_risk="589"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Paroxysmal Atrial Tachycardia (PAT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Permanent atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Persistent atrial fibrillation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Supraventricular Tachycardia (SVT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Tachy-bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Tachycardia - Non-ventricular</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Tachycardia - Ventricular</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiovascular - Other</sub_title>
                <counts group_id="E1" events="95" subjects_affected="85" subjects_at_risk="589"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Heart failure - Acute</sub_title>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Heart Failure - Chronic (CHF)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypertension - Pulmonary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypertension - Systemic</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="38" subjects_at_risk="589"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Perforation - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pericardial effusion - Minor</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Bilateral</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="589"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Left</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="589"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pleural effusion - Right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Aortic-central/Transvalvular +3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-central/Transvalvular +1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-central/Transvalvular +2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-central/Transvalvular +3</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-central/Transvalvular +4</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-indeterminate +2</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Mitral-indeterminate +3</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Tricuspid-indeterminate +3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Regurgitation - Tricuspid-indeterminate +4</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thromboembolic event - Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Thromboembolic event - Transient Ischemic Attack (TIA)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary (gallbladder)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Endocrine complications</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="589"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="589"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hepatic complication - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Liver Failure - Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Metabolic complications</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pancreatic complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction - Medication related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Allergic reaction - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cancer - Progression of underlying disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Fever - Unknown origin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hearing disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Nonspecific, unknown, or other body system - Other complication</sub_title>
                <counts group_id="E1" events="133" subjects_affected="108" subjects_at_risk="589"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>NSD - Paravalvular leak +1 Minor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>NSD - Paravalvular leak +2 Minor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>NSD - Paravalvular leak +3 Major</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vision disorder</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture/Break</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Infection/Inflammation - Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Muscular skeletal/Dermatologic - Other</sub_title>
                <counts group_id="E1" events="103" subjects_affected="87" subjects_at_risk="589"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Sternal wound/Thoracic infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Wound infection - Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric - Other</sub_title>
                <counts group_id="E1" events="46" subjects_affected="44" subjects_at_risk="589"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Psychiatric disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Transient psychotic syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary - Other</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal dysfunction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal failure - Acute</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="589"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Renal failure - Chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="589"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="122" subjects_affected="122" subjects_at_risk="589"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism - Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism - Right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pulmonary/Respiratory - Other</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="589"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory dysfunction/Insufficiency</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Acute Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - COPD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory failure - Pneumothorax</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="589"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory infection - Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Respiratory infection - Upper (URI)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="589"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular - Access site complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="589"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vascular - Deep Vein Thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="589"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 30 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 60 day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrey Nersesov, Sr. Director of Clinical Affairs, Surgical Structural Heart</name_or_title>
      <organization>Edwards Lifesciences, LLC</organization>
      <phone>949-250-2500 ext 0225</phone>
      <email>Andrey_Nersesov@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

